Journal of Science Policy & Governance | Volume 17, Issue 01 | September 30, 2020
|
Policy Memo: Federal Policy for Lowering Prescription Drug Prices
Amanda Hurley (1), Celeste M. Sheftel (2), Alejandra Canales (3)
|
Keywords: drug pricing, prescriptions, law, healthcare, patents, drug patent exemption
Executive Summary: Both Republicans and Democrats are determined to lower the escalating cost of prescription drug prices, which is projected to reach $605 billion/yr by 2026 (Committee on Ways and Means 2019). In this memorandum, we explore the possible outcomes of,
We recommend that the next presidential candidate approve Option 2 and advocate for HHS Secretary negotiation powers with patent exemptions for non-compliant companies.
- linking U.S. drug prices to the international median incentivized by re-importation of the U.S.-made drugs from other countries,
- allowing the Secretary of Health and Human Services (HHS) to negotiate Medicare part D drugs incentivized through patent exemption and,
- funding drug discovery through prizes instead of market-exclusive patents.
We recommend that the next presidential candidate approve Option 2 and advocate for HHS Secretary negotiation powers with patent exemptions for non-compliant companies.
-Read the full article through download.- |
References
- Azar, Alex. 2020. “Federal Health Officials Testify on Coronavirus and 2021 Budget Request.” C-SPAN.org. February 26, 2020. https://www.c-span.org/video/?469562-1/federal-health-officials-testify-coronavirus-2021-budget-request&start=10861
- Bhosle, Monali J., and Rajesh Balkrishnan. 2007. “Drug Reimportation Practices in the United States.” Therapeutics and Clinical Risk Management 3 (1): 41–46.
- Biniek, Jean Fuglesten, and William Johnson. 2019. “Spending on Individuals with Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices.” Health Care Cost Institute.
- Blankenship, Kyle. 2019. “The Top 20 Drugs by 2018 U.S. Sales.” FiercePharma. Accessed April 4, 2020. https://www.fiercepharma.com/special-report/top-20-drugs-by-2018-u-s-sales.
- Cefalu, William, T., Dawes, Daniel E., Gavlak, Gina, Goldman, Dana, Herman, William H., van Nuys, Karen, Powers, Alvin C., Taylor, Simeon I., and Alan L. Yatvin. 2018. “Insulin Access and Affordability Working Group: Conclusions and Recommendations.” Diabetes Care. 41(6):1299-1311. http://dx.doi.org/10.2337/dci18-0019
- Chapman, Audrey R., and Thomas Buckley. 2017. “Lowering the High Cost of Hepatitis C Drugs.” Journal of Pharmaceutical Care & Health Systems. https://doi.org/10.4172/2376-0419.1000187.
- Cohen, Robin A., Peter Boersma, and Anjel Vahratian. 2019. “Strategies Used by Adults Aged 18-64 to Reduce Their Prescription Drug Costs, 2017.” NCHS Data Brief, no. 333 (March): 1–8.
- Committee on Ways and Means. 2019. “A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices.” Accessed April 9, 2020. https://waysandmeans.house.gov/sites/democrats.waysandmeans.house.gov/files/documents/U.S.%20vs.%20International%20Prescription%20Drug%20Prices_0.pdf.
- Congresswoman Jan Schakowsky. 2020. “House Democrats Demand Fair Drug Pricing For Taxpayer-Funded Coronavirus Vaccine or Treatment.” February 20, 2020. https://schakowsky.house.gov/media/press-releases/house-democrats-demand-fair-drug-pricing-taxpayer-funded-coronavirus-vaccine-or.
- Dossey, Larry. 2019. “The Insulin Caravans: What Price Life?” Explore. November. https://doi.org/10.1016/j.explore.2019.11.001.
- Emanuel, Ezekiel J. 2019. “Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up.” The Atlantic. March 23, 2019. https://www.theatlantic.com/health/archive/2019/03/drug-prices-high-cost-research-and-development/585253/.
- Fox, Erin. 2017. “How Pharma Companies Game the System to Keep Drugs Expensive.” Harvard Business Review. April 6, 2017. https://hbr.org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive.
- Grassley, Chuck. 2019. “S.2543 - 116th Congress (2019-2020): Prescription Drug Pricing Reduction Act of 2019,” September. https://www.congress.gov/bill/116th-congress/senate-bill/2543.
- Johnson, Nicole. 2005. “Canadian Drug Reimportation Debate Goes on.” Drug Discovery Today. 10 (10):678-9 https://doi.org/10.1016/s1359-6446(05)03456-2.
- Lichtenberg, Frank R. and Shawn X. Sun. 2007. The Impact Of Medicare Part D On Prescription Drug Use By The Elderly. Health Affairs. Accessed April 4, 2020a. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.26.6.1735.
- Meadows, Michelle. 2002. “Imported Drugs Raise Safety Concerns.” FDA Consumer 36 (5): 18–23.
- Mikuli, Matej. 2019 “Health Care Expenditure Distribution by Payer U.S. 2019.” Statista. Accessed April 4, 2020. https://www.statista.com/statistics/237043/us-health-care-spending-distribution/.
- National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, and Committee on a National Strategy for the Elimination of Hepatitis B and C. 2016. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. National Academies Press.
- Office of the Commissioner. 2018. “Statement from FDA Commissioner Scott Gottlieb, M.D., on New Policies to Reduce the Ability of Brand Drug Makers to Use REMS Programs as a Way to Block Timely Generic Drug Entry, Helping Promote Competition, and Access.” U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-policies-reduce-ability-brand-drug-makers-use-rems.
- Pallone, Frank Jr. 2019. “H.R.3 - 116th Congress (2019-2020): Elijah E. Cummings Lower Drug Costs Now Act,” December. https://www.congress.gov/bill/116th-congress/house-bill/3.
- Right Care Alliance. 2019 “High Insulin Costs Are Killing Americans - Right Care Alliance.”Accessed April 4, 2020. https://rightcarealliance.org/actions/insulin/.
- Russo, Alice. A., and Jason Johnson. 2015. “Research Use Exemptions to Patent Infringement for Drug Discovery and Development in the United States.” Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a020933.
- Safran, Dana Gelb, Neuman, Patricia, Schoen, Cathy, Montgomery, Jana E. Li, Wenjun, Wilson, Ira B., Kitchman, Michelle S., Bowen, Andrea E., and William H. Rogers. 2002. “Prescription Drug Coverage and Seniors: How Well Are States Closing the Gap?” Health Affairs Suppl Web Exclusives (July): W253–68.
- Sanders, Bernard 2017. “S.495 - 115th Congress (2017-2018): Medical Innovation Prize Fund Act,” https://www.congress.gov/bill/115th-congress/senate-bill/495/
- Segal, Troy. 2010. “Price Ceiling.” Investopedia. August 8, 2010. https://www.investopedia.com/terms/p/price-ceiling.asp.
- Simmons-Duffin, Selena. 2020. “Where That $8.3 Billion In U.S. Coronavirus Funding Will And Won’t Go.” NPR.org. March 6, 2020. https://www.npr.org/sections/health-shots/2020/03/06/812964894/where-that-8-3-billion-in-u-s-coronavirus-funding-will-and-wont-go.
- Swagel, Philip L. 2019. “Effects of Drug Price Negotiation Stemming From Title 1 of H.R. 3, the Lower Drug Costs Now Act of 2019, on Spending and Revenues Related to Part D of Medicare.” Congressional Budget Office. Accessed April 4, 2020b. https://www.cbo.gov/system/files/2019-10/hr3ltr.pdf.
- T1interational. 2018 “Costs and Rationing of Insulin and Diabetes Supplies: Findings from the T1international Patient Survey.” Accessed July 16, 2020. https://www.t1international.com/media/assets/file/T1International_Report_-_Costs_and_Rationing_of_Insulin__Diabetes_Supplies_2.pdf
- 21 USC. Sec 321. 2012. “Definitions; Generally.” Accessed April 4, 2020. https://uscode.house.gov/view.xhtml?req=(title:21%20section:321%20edition:prelim
- 42 USC. Sec 262. 2011. “Regulation of Biological Products.” Accessed April 4, 2020. https://uscode.house.gov/view.xhtml?req=(title:42%20section:262%20edition:prelim
- U.S. Government Accountability Office. 2017. “Drug Industry: Profits, Research and Development Spending, and Merger and Acquisition Deals,” no. GAO-18-40 (December). https://www.gao.gov//assets/690/688472.pdf/
Amanda Hurley received a Ph.D. in Molecular Biology with Dr. Bonnie Bassler at Princeton University in 2017. She serves as the professional development chair for Catalysts for Science Policy, is a former eLife Ambassador, and sits on the board for the early career research nonprofit group, Future of Research.
Celeste M. Sheftel is a 5th year Ph.D. candidate in the Molecular and Cellular Pharmacology Training Program at the University of Wisconsin-Madison in Dr. Laura Hernandez’s lab. She serves on the professional development committee for Catalysts for Science Policy and is the national liaison for the Madison Chapter of the Graduate Women in Science.
Alejandra Canales is a 7th year Ph.D. candidate in the Neuroscience Training Program at the University of Wisconsin-Madison in Dr. Meyer Jackson’s lab. She is passionate about advocating for graduate students and serves on the policy engagement committee for Catalysts in Science Policy as well as the Diversity Enhancement Committee for the Neuroscience Training Program.
Acknowledgements
The authors of this memo are members of Catalysts for Science Policy at the University of Wisconsin – Madison, which belongs to the Central Hub of the National Science Policy Network (NSPN). The authors would like to thank Dr. Stephanie Davis and Nabanita Nawar for their input and copyediting of this document.
Celeste M. Sheftel is a 5th year Ph.D. candidate in the Molecular and Cellular Pharmacology Training Program at the University of Wisconsin-Madison in Dr. Laura Hernandez’s lab. She serves on the professional development committee for Catalysts for Science Policy and is the national liaison for the Madison Chapter of the Graduate Women in Science.
Alejandra Canales is a 7th year Ph.D. candidate in the Neuroscience Training Program at the University of Wisconsin-Madison in Dr. Meyer Jackson’s lab. She is passionate about advocating for graduate students and serves on the policy engagement committee for Catalysts in Science Policy as well as the Diversity Enhancement Committee for the Neuroscience Training Program.
Acknowledgements
The authors of this memo are members of Catalysts for Science Policy at the University of Wisconsin – Madison, which belongs to the Central Hub of the National Science Policy Network (NSPN). The authors would like to thank Dr. Stephanie Davis and Nabanita Nawar for their input and copyediting of this document.
DISCLAIMER: The findings and conclusions published herein are solely attributed to the author and not necessarily endorsed or adopted by the Journal of Science Policy and Governance. Articles are distributed in compliance with copyright and trademark agreements.
ISSN 2372-2193
ISSN 2372-2193